1.Biofourmis: $320 million (Cardiovascular)
Biofourmis developed the Biovitals Analytics Engine. [Image courtesy of Biofourmis]
The Boston-based company develops software for virtual care management and pharmaceutical development. It has FDA 510(k) clearances for its Biovitals Analytics Engine and RhythmAnalytics, two devices using proprietary algorithms to measure and analyze health data.
Biofourmis raised the funding in a Series D round that included an investment from Intel Capital, the strategic investment arm of semiconductor manufacturer Intel Corp.
“Biofourmis is laser-focused on delivering real-time patient insight to clinicians to improve the home-based care experience,” Intel Capital VP and Senior Managing Director Mark Rostick said in a news release at the time. “Through edge computing and edge-to-cloud processing capabilities, Biofourmis is redefining the patient and provider journey leveraging advanced technology.”
Biofourmis was founded in 2016 by CEO Kuldeep Singh Rajput, Chief Privacy Officer Mark Niu and Chief Medical Officer Maulik Majmudar.
The leaders planned to use the funding round to scale their technology and build new digital companion therapeutics.
